You would think that SOME form of news release would be prudent, if for no other reason than to clearly differentiate for the masses the chemistry differences between the two drugs, and yes, the excellent safety profile of Eteplirsen.
Please be realistic, people. This isn't a pump and dump. The CEO isn't going to immediately follow up the GSK article to say, "See? We're safe and they aren't." You can be certain this question will be raised and addressed at the next medical conference. It is absolutely not worthy of a PR. Besides, we already know eterplirsen is safe because they've told us many times over.